The clinical importance of proton pump inhibitor pharmacokinetics.
Achieving the optimal clinical response for patients with upper gastrointestinal peptic disease is important. This response depends on the pathology treated as well as on the choice of proton pump inhibitor. Here, we identify factors in specific disease therapy and proton pump inhibitor (PPI) pharmacokinetic and pharmacodynamic characteristics that help us achieve this goal. These include differences in PPI bioavailability and acid-suppressive effects. Available data indicate that PPIs appear to have similar potency on a milligram basis, and that omeprazole and lansoprazole are more frequently double dosed than pantoprazole. The lower propensity for double dosing with pantoprazole may also result in lower medication acquisition costs and a reduction in physician visits due to ineffective therapy with the standard dosing of these other agents.
Yacyshyn
B R
BR
Department of Medicine, Division of Gastroenterology, University of Alberta, Edmonton, Canada. bruce.yacyshyn@med.va.gov
Thomson
A B R
AB
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001562:Benzimidazoles / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D017046:Cost Savings; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000378:metabolism; D005764:Gastroesophageal Reflux / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D009853:Omeprazole / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000077402:Pantoprazole; D054328:Proton Pump Inhibitors; D013454:Sulfoxides / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D054328:Proton Pump Inhibitors; D013454:Sulfoxides; D000077402:Pantoprazole; D009853:Omeprazole